435 Studies Now Enrolling
A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic, Recurrent, Injectable Solid Tumors, with Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic Solid Tumors
| Sponsor: | Codiak BioSciences, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAT4058 |
| U.S. Govt. ID: | NCT04592484 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test the safety and dose of CDK-002 alone in subjects with cancer that is considered advanced and/or has spread to other parts of the body. CDK-002 is an investigational study drug that is being developed for the potential treatment of cancer. This is a first-in-human study. CDK-002 is a drug designed to activate the immune system so that it tries to kill cancer cells. CDK-002 will be injected directly into cancer tumors. This may be done using a CT scan or an ultrasound to help guide the injection. Cancers include breast cancer, head and neck/oral cancers, skin cancers, melanoma, and thyroid cancer.
This study is closed
